Fig. 3: Saracatinib inhibited necroptosis through targeting downstream of RIPK3.
From: Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL
A L929 cells were pretreated with DMSO or saracatinib (7.5 μM) for 1 h following treatment with TNF for indicated time. Then the cells were harvested and analyzed with the indicated antibodies (n = 3). B and C L929 (B) or HT-29 (C) cells were pretreated with DMSO or saracatinib (7.5 μM) for 1 h following treatment with TSZ for indicated time. Then the cells were harvested and analyzed with the indicated antibodies (n = 3). D BMDM cells were pretreated with DMSO or saracatinib (7.5 μM) for 1 h following treatment with LPS + z-VAD. Then the cells were harvested and analyzed with the indicated antibodies (n = 3). E Mouse RIPK3-flag reconstituted RIPK3-KO L929 cells were pretreated DMSO or saracatinib (7.5 μM) for 1 h following treatment with TNF + zVAD (TZ). Then the cells were harvested and immunoprecipitated with M2 (anti-flag) antibody. The total cell lysates (TCL) and the immunoprecipitates were immunoblotted with the indicated antibodies (n = 3). See also Fig. S3.
